PT1317921E - Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações - Google Patents

Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações Download PDF

Info

Publication number
PT1317921E
PT1317921E PT01403166T PT01403166T PT1317921E PT 1317921 E PT1317921 E PT 1317921E PT 01403166 T PT01403166 T PT 01403166T PT 01403166 T PT01403166 T PT 01403166T PT 1317921 E PT1317921 E PT 1317921E
Authority
PT
Portugal
Prior art keywords
gel
dht
manufacture
solution containing
dihydrotestosterone
Prior art date
Application number
PT01403166T
Other languages
English (en)
Inventor
Valerie Masini-Eteve
Brigitte Taravella
Original Assignee
Besins Mfg Belgium
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Mfg Belgium filed Critical Besins Mfg Belgium
Publication of PT1317921E publication Critical patent/PT1317921E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
PT01403166T 2001-12-07 2001-12-07 Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações PT1317921E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403166A EP1317921B1 (fr) 2001-12-07 2001-12-07 Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations

Publications (1)

Publication Number Publication Date
PT1317921E true PT1317921E (pt) 2009-11-06

Family

ID=8183007

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01403166T PT1317921E (pt) 2001-12-07 2001-12-07 Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações

Country Status (12)

Country Link
US (1) US20030087885A1 (pt)
EP (1) EP1317921B1 (pt)
AT (1) ATE439829T1 (pt)
AU (1) AU2002364625A1 (pt)
CA (1) CA2469028C (pt)
CY (1) CY1110602T1 (pt)
DE (1) DE60139625D1 (pt)
DK (1) DK1317921T3 (pt)
ES (1) ES2330188T3 (pt)
MX (1) MXPA04005517A (pt)
PT (1) PT1317921E (pt)
WO (1) WO2003047548A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1347764B1 (de) * 2000-12-22 2007-03-14 Dr. August Wolff GmbH & Co. KG Arzneimittel Gelzusammensetzung auf alkoholischer basis zur behandlung von hypogonadismus durch transskrotale applikation
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
EP1572171B1 (en) * 2002-12-18 2009-04-22 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
SI1572178T1 (sl) * 2002-12-18 2006-10-31 Besins Int Lab Zdravljenje mastalgije s 4-hidroksi-tamoksifenom
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DK1631275T3 (da) * 2003-06-09 2008-08-18 Ascend Therapeutics Inc Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
WO2005007100A2 (en) * 2003-07-11 2005-01-27 Macrochem Corporation Pharmaceutical compositions for topical application
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
ES2310765T3 (es) * 2003-12-15 2009-01-16 Laboratoires Besins International Uso de 4-hidroxitamoxifeno para la preparacion de un medicamento para el tratamiento de ginecomastia.
EP1550440A1 (en) * 2003-12-15 2005-07-06 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
CA2559748C (en) * 2004-03-22 2013-05-28 Elisabeth Le Nestour Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EA013430B1 (ru) * 2004-09-09 2010-04-30 Лаборатуар Безен Энтернасьональ Тестостероновые гели, включающие пропиленгликоль в качестве усилителя проницаемости
KR20080016552A (ko) * 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법
EP2450041B1 (en) 2005-10-12 2018-09-26 Unimed Pharmaceuticals, LLC Improved testosterone gel for use in the treatment of hypogonadism
WO2007045027A1 (en) * 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
AU2012200290B2 (en) * 2005-10-19 2014-08-21 Havah Therapeutics Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
WO2013006917A1 (en) * 2011-07-14 2013-01-17 Sunnywipes Pty Ltd Disinfecting formulations and uses thereof
US9351977B2 (en) 2014-10-22 2016-05-31 Chavah Pty Ltd. Methods of reducing mammographic breast density and/or breast cancer risk
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CN109276539A (zh) * 2018-11-08 2019-01-29 北京海霞润月更年期综合症医学研究院 一种睾酮凝胶及制备方法
WO2020243777A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519252A1 (fr) 1982-01-07 1983-07-08 Besins Jean Medicament a base de dihydrotestosterone pour le traitement des deficits des secretions androgeniques testiculaires
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
EP0952833A1 (de) * 1996-05-02 1999-11-03 Azupharma GmbH Topische penile androgen-applikation zur behandlung der erektilen dysfunktion
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers

Also Published As

Publication number Publication date
EP1317921B1 (fr) 2009-08-19
WO2003047548A1 (fr) 2003-06-12
DE60139625D1 (de) 2009-10-01
ES2330188T3 (es) 2009-12-07
CY1110602T1 (el) 2015-04-29
CA2469028A1 (fr) 2003-06-12
DK1317921T3 (da) 2009-12-21
AU2002364625A1 (en) 2003-06-17
EP1317921A1 (fr) 2003-06-11
ATE439829T1 (de) 2009-09-15
CA2469028C (fr) 2012-08-14
MXPA04005517A (es) 2005-03-23
US20030087885A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
PT1317921E (pt) Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
AU2001287892A1 (en) Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
MY137535A (en) New pyrrolidinium derivatives
IS6658A (is) Ný efnasambönd
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
EP2289531A3 (en) Medicaments for increasing endogenous erythropoietine (EPO)
GB9813540D0 (en) Chemical compounds
ZA979961B (en) 5-HT1F agonists
HK1001374A1 (en) Nimesulide for external use
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
ATE293595T1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
IL132599A0 (en) Substituted 3,3-diamino-2-propenenitriles their preparation and use
IL151647A0 (en) Novel lhrh-antagonists, production and use thereof as medicament
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
AU589240B2 (en) Sulfinyl and sulfonyl substituted-3-benzazepine
HUP0200529A2 (en) Optically pure camptothecin analogues, pharmaceutical compositions containing them and their use
WO2000045894A3 (de) Verwendung von pyrazol-carbonsäureamiden
FR2769839B1 (fr) Composition anhydre a base de lactulose
ZA941196B (en) Angiopeptin cyclopeptide compounds process for the preparation thereof and pharmaceutical compositions containing them
EP1269976A3 (de) Mittel zum Blondieren von menschlichen Haaren
BR0301299A (pt) Kit para a tintura de fibras queratìnicas, composição oxidante, processo de tintura de oxidação das fibras queratìnicas, dispositivo com vários compartimentos e composição pronta para o uso